Information Provided By:
Fly News Breaks for April 10, 2019
BIIB
Apr 10, 2019 | 09:24 EDT
Raymond James analyst Steven Seedhouse resumed coverage of Biogen with a Market Perform rating, stating that the company's remaining business following the failure of aducanumab "appears a little fragile" and faces "existential risk" in some cases, such as the Tecfidera IPR decision due in 2020. Near-term pipeline readouts, including the nearest readouts on Vumerity and BIIB067, don't seem high-impact enough to reverse sentiment, Seedhouse tells investors.
News For BIIB From the Last 2 Days
BIIB
BIIB
BIIB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.